Atıf İçin Kopyala
BEKSAÇ M., Aydin Y., GÖKER H., Turgut M., Besisik S., Cagirgan S., ...Daha Fazla
Clinical lymphoma, myeloma & leukemia, cilt.20, sa.8, 2020 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
20
Sayı:
8
-
Basım Tarihi:
2020
-
Doi Numarası:
10.1016/j.clml.2020.02.017
-
Dergi Adı:
Clinical lymphoma, myeloma & leukemia
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
-
Anahtar Kelimeler:
EAP, Efficacy, RRMM, Safety, Survival, REFRACTORY MULTIPLE-MYELOMA, HISTORICAL CONTROL DATA, OPEN-LABEL, SURVIVAL, EFFICACY, CD38
-
İstanbul Üniversitesi Adresli:
Evet
Özet
The present study investigated the efficacy and safety profile of daratumumab monotherapy in 42 patients with relapsed refractory multiple myeloma through a Turkish early access program. The current findings have confirmed the efficacy of daratumumab monotherapy in heavily pretreated patients with refractory multiple myeloma because of the deep and durable responses and favorable safety and tolerability profile.